101 related articles for article (PubMed ID: 30807642)
1. CA125 over-release behavior following a 75-g oral glucose test as a predictive biomarker of multidrug resistance in patients with ovarian cancer.
He Y; Gu Z; Zhu Q; Chen M; He C; Huang Y; Li Q; Di W
Int J Cancer; 2019 Sep; 145(6):1690-1700. PubMed ID: 30807642
[TBL] [Abstract][Full Text] [Related]
2. Postprandial increase in serum CA125 as a surrogate biomarker for early diagnosis of ovarian cancer.
Gu Z; He Y; Zhang Y; Chen M; Song K; Huang Y; Li Q; Di W
J Transl Med; 2018 May; 16(1):114. PubMed ID: 29716620
[TBL] [Abstract][Full Text] [Related]
3. Clinical Significance of CA125 Level after the First Cycle of Chemotherapy on Survival of Patients with Advanced Ovarian Cancer.
Lee M; Chang MY; Yoo H; Lee KE; Chay DB; Cho H; Kim S; Kim YT; Kim JH
Yonsei Med J; 2016 May; 57(3):580-7. PubMed ID: 26996555
[TBL] [Abstract][Full Text] [Related]
4. Correlation between CA125 levels after sixth cycle of chemotherapy and clinical outcome in advanced ovarian carcinoma.
Gadducci A; Menichetti A; Guiggi I; Notarnicola M; Cosio S
Anticancer Res; 2015 Feb; 35(2):1099-104. PubMed ID: 25667499
[TBL] [Abstract][Full Text] [Related]
5. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
[TBL] [Abstract][Full Text] [Related]
6. Combined score of pretreatment platelet count and CA125 level (PLT-CA125) stratified prognosis in patients with FIGO stage IV epithelial ovarian cancer.
Chen JP; Huang QD; Wan T; Tu H; Gu HF; Cao JY; Liu JH
J Ovarian Res; 2019 Jul; 12(1):72. PubMed ID: 31362750
[TBL] [Abstract][Full Text] [Related]
7. CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer: a population-based study.
van Altena AM; Kolwijck E; Spanjer MJ; Hendriks JC; Massuger LF; de Hullu JA
Gynecol Oncol; 2010 Nov; 119(2):265-9. PubMed ID: 20797777
[TBL] [Abstract][Full Text] [Related]
8. Serum CA125 levels predict outcome of interval debulking surgery after neoadjuvant chemotherapy in patients with advanced ovarian cancer.
Zhang D; Jiang YX; Luo SJ; Zhou R; Jiang QX; Linghu H
Clin Chim Acta; 2018 Sep; 484():32-35. PubMed ID: 29702068
[TBL] [Abstract][Full Text] [Related]
9. The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study.
Nassir M; Guan J; Luketina H; Siepmann T; Rohr I; Richter R; Castillo-Tong DC; Zeillinger R; Vergote I; Van Nieuwenhuysen E; Concin N; Marth C; Hall C; Mahner S; Woelber L; Sehouli J; Braicu EI
Tumour Biol; 2016 Mar; 37(3):3009-16. PubMed ID: 26419591
[TBL] [Abstract][Full Text] [Related]
10. The lack of significance of Ca125 response in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking.
Le T; Hopkins L; Faught W; Fung-Kee-Fung M
Gynecol Oncol; 2007 Jun; 105(3):712-5. PubMed ID: 17400284
[TBL] [Abstract][Full Text] [Related]
11. Personalized ovarian cancer disease surveillance and detection of candidate therapeutic drug target in circulating tumor DNA.
Martignetti JA; Camacho-Vanegas O; Priedigkeit N; Camacho C; Pereira E; Lin L; Garnar-Wortzel L; Miller D; Losic B; Shah H; Liao J; Ma J; Lahiri P; Chee M; Schadt E; Dottino P
Neoplasia; 2014 Jan; 16(1):97-103. PubMed ID: 24563622
[TBL] [Abstract][Full Text] [Related]
12. Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.
Shen Y; Li L
Tumour Biol; 2016 Nov; 37(11):14765-14772. PubMed ID: 27629144
[TBL] [Abstract][Full Text] [Related]
13. Postoperative human epididymis protein 4 predicts primary therapy outcome in advanced epithelial ovarian cancer.
Vallius T; Hynninen J; Auranen A; Matomäki J; Oksa S; Roering P; Grènman S
Tumour Biol; 2017 Feb; 39(2):1010428317691189. PubMed ID: 28218038
[TBL] [Abstract][Full Text] [Related]
14. Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy.
Han LY; Karavasilis V; Hagen Tv; Nicum S; Thomas K; Harrison M; Papadopoulos P; Blake P; Barton DP; Gore M; Kaye SB
Eur J Cancer; 2010 May; 46(8):1359-64. PubMed ID: 20303743
[TBL] [Abstract][Full Text] [Related]
15. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients.
Holloway RW; Mehta RS; Finkler NJ; Li KT; McLaren CE; Parker RJ; Fruehauf JP
Gynecol Oncol; 2002 Oct; 87(1):8-16. PubMed ID: 12468336
[TBL] [Abstract][Full Text] [Related]
16. Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer.
Kang WD; Choi HS; Kim SM
Gynecol Oncol; 2010 Jan; 116(1):57-60. PubMed ID: 19818996
[TBL] [Abstract][Full Text] [Related]
17. Elevated preoperative plasma D-dimer level is a useful predictor of chemoresistance and poor disease outcome for serous ovarian cancer patients.
Liu P; Wang Y; Tong L; Xu Y; Zhang W; Guo Z; Ni H
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1163-71. PubMed ID: 26542279
[TBL] [Abstract][Full Text] [Related]
18. Monitoring ovarian cancer patients during chemotherapy and follow-up with the serum tumor marker CA125.
Abu Hassaan SO
Dan Med J; 2018 Apr; 65(4):. PubMed ID: 29619933
[TBL] [Abstract][Full Text] [Related]
19. Elevated Serum Level of CA125 Is a Biomarker That Can Be Used to Alter Prognosis Determined by BRCA Mutation and Family History in Ovarian Cancer.
Liu W; Wang Z; Ma J; Hou Y; Zhao J; Dong B; Tu S; Wang L; Guo Y
Genet Test Mol Biomarkers; 2017 Sep; 21(9):547-554. PubMed ID: 28799806
[TBL] [Abstract][Full Text] [Related]
20. Importance of CA125 normalization during neoadjuvant chemotherapy followed by planned delayed surgical debulking in patients with epithelial ovarian cancer.
Le T; Faught W; Hopkins L; Fung-Kee-Fung M
J Obstet Gynaecol Can; 2008 Aug; 30(8):665-670. PubMed ID: 18786288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
